Welcome to the World of CECOG

Publications

Metastatic Breast Cancer
- The manuscript "Gemcitabine, Epirubicin and Paclitaxel Versus Fluorouracil, Epirubicin and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial" has been published in the Journal of Clinical Oncology, volume 23, number 7, issue March 1st, 2005.
  
  Download Journal of Clinical Oncology - Original Report (pdf - 169kb)
- Gemcitabine, Epirubicin and Paclitaxel (GET) vs. 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) as First-Line Treatment in Metastatic Breast Cancer (MBC): Demographics of a Randomised, Multicenter Phae III Trial of the Central European Cooperative Oncology (CECOG).
  
  C. Zielinski, S. Beslija, Z. Mrsic-Krmpotic, J. Jassem, C. Wiltschke, Z. Kahan, M. Grgic, V. Tzekova, M. Inbar, T. Brodowicz.
  
  ASCO 2003
- Gemcitabine, Epirubicin and Paclitaxel (GET) vs. 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) as First-Line Treatment in Metastatic Breast Cancer: Interim Toxicity Analysis of a Randomised, Multicenter Phase III Trial of the Central European Cooperative Oncology Group (CECOG).
  
  C. Zielinski, S. Beslija, J. Cervek, Z. Mrsic-Krmpotic, I. Tchernozemsky, C. Wiltschke, N. Ghilezan, M. Grgic, J. Jassem, V. Tzekova, Z. Kahan, J. Pawlega, H. Onat, M. Inbar, and T. Brodowicz for the Central European Cooperative Oncology Group.
  
  ASCO, 2001
- Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluorouracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase III trial of the Central European Cooperative Oncology Group (CECOG).
  
  T. Brodowicz, S. Beslija, J. Cervek, Z. Mrsic-Krmpotic, I. Tchernozemsky, C. Wiltschke, N. Ghilezan, M. Grgic, J. Jassem, C. Zielinski for the Central European Cooperative Oncology Group.
  
  ECCO 2001
Non-Small Cell Lung Cancer
- The manuscript "Cisplatin and Gemcitabine First-Line Cheomtherapy Followed by Maintenance Gemcitabine or Best Supportive Care in Advanced Non-Small Cell Lung Cancer: A Phase III Trial" has been published in Lung Cancer (2006) vol. 52; p155 - 163).
  
  Download: article (pdf - 257kb)
- Gemcitabine and Cisplatin (GC) +/- Subsequent Maintenance Therapy with Single-Agent Gemcitabine in Advanced Non-small Cell Lung Cancer (NSCLC): Preliminary Results of a Randomized Trial of the Central European Cooperative Oncology Group (CECOG).
  
  M. Krzakowski, M. Wenczl, T. Brodowicz, V. Tzekova, R. Ramlau, N. Ghilezan, B. Cucevic, K. Gyurkovits, E. Ulsperger, C. Zielinski, M. Zwitter.
  
  World Conference on Lung Cancer, 2003
- Gemcitabine and Cisplatin (GC) +/- Subsequent Maintenance Therapy with Single-Agent Gemcitabine in Advanced Non-small Cell Lung Cancer (NSCLC): Preliminary Results of a Randomized Trial of the Central European Cooperative Oncology Group (CECOG).
  
  M. Krzakowski, M. Wenczl, T. Brodowicz, V. Tzekova, R. Ramlau, N. Ghilezan, B. Cucevic, E. Ulsperger, C. Zielinski, M. Zwitter.
  
  Proc. Am. Soc. Clin. Oncol. 2004
- Delay in time to worsening of symptoms of advanced non-small cell lung cancer patients using gemcitabine maintenance therapy.
  
  P. Peterson, M. Zwitter, M. Krzakowski, M. Wenczl, V. Tzekova, R. Ramlau, T. Ciuleanu, A. Liepa, C. Zielinski, T. Brodowicz
  
  Supplement to Journal of Clin. Oncol. 2006, 24, 399s, abstract 7140
Gastrointestinal Cancer

Gemcitabine plus Capecitabine versus Gemcitabine alone in advanced pancreatic cancer. A randomized phase III trial

Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group.

Journal of Clinical Oncology, 2007, 25: 2212-2217.
Gemcitabine plus Capecitabine versus Gemcitabine alone in advanced pancreatic cancer. A randomized phase III trial.

R. Herrmann, G. Bodoky, T. Ruhstaller, B. Glimelius, P. Saletti, E. Bajetta, J. Schueller, J. Bernhard, D. Dietrich, W. Scheithauer.

Proc.Am.Soc.Clin.Oncol (Abstract No: 4010, Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005:4010
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS 1.2.001

M. Hejna, J. Zacherl, A Ba-Ssalamah, A. Püspök, U. Pluschnig, T. Brodowicz, C. Zielinski, M. Raderer

Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4527 and Anti Cancer drugs (in press).

Colorectal Cancer

A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients with metastatic colorectal cancer.

T. Ciuleanu, W. Scheithauer, G. Kurteva, J. Ocvirk, I. Koza, D. Papamichael, M. Wenczl, T. Brodowicz, C. Zielinski, S. Beslija.

ECCO, 2007 (#3046).
Cetuximab plus FOLFOX-6 versus cetuximab plus FOLFIRI as first-line therapy in patients with metastatic colorectal cancer: A randomized, open-label phase II CECOG study.

T. Ciuleanu, W. Scheithauer, G. Kurteva, J. Ocvirk, I. Koza, D. Papamichael, M. Wenczl, T. Brodowicz, C. Zielinski, S. Beslija.

ASCO GI 2008, (#339).

Early Breast Cancer

Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised CECOG study

Z. Kahán, S. Spanik, M. Wagnerova, T. Skacel, B. Planko, E. Fitzthum, E. Lindner, V. Soldatenkova, C. Zielinski, T. Brodowicz.

Breast Cancer Research and Treatment (in press)
A randomized, open-label CECOG phase II study of dose-dense FEC 75 vs FEC 90 as adjuvant therapy in early breast cancer patients.

Z. Kahán, S. Spanik, M. Wagnerova, T. Skacel, B. Planko, E. Fitzthum, E. Lindner, V. Soldatenkova, C. Zielinski, T. Brodowicz.

ECCO 2007 (#2095)

For publications of the results of the Consensus Conferenences
see Consensus Statements